Ahmed A. Abdelghany

Ahmed A. Abdelghany

Auto-generated profile, based on publicly available information

Ahmed A. Abdelghany

Department of Ophthalmology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2019 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
ETEman Toraih
Eman Toraih
AAAhmed A. Abdelghany
Ahmed A. Abdelghany
Noha M. Abd El-FadealNoha M. Abd El-Fadeal
Noha M. Abd El-Fadeal
EAEssam Al Ageeli
Essam Al Ageeli
Manal S. FawzyManal S. Fawzy
Manal S. Fawzy

1 September 2019 in Experimental Eye Research
Verified
Journal Article
Closed access
HBHoda I. Bahr
Hoda I. Bahr
AAAhmed A. Abdelghany
Ahmed A. Abdelghany
RGRania A. Galhom
Rania A. Galhom
BBBassant Barakat
Bassant Barakat
EAEl-Shaimaa A. Arafa
El-Shaimaa A. Arafa
Manal S. FawzyManal S. Fawzy
Manal S. Fawzy

30 January 2020 in Bosnian Journal of Basic Medical Sciences
Verified
Journal Article
Open access
PDF file
Manal S. FawzyManal S. Fawzy
Manal S. Fawzy
AAAhmed A. Abdelghany
Ahmed A. Abdelghany
ETEman Toraih
Eman Toraih
AMAbeer M. Mohamed
Abeer M. Mohamed
Recently, a wide range of biological and pathological roles of long noncoding RNAs (lncRNAs) have been discovered. However, the potential role of circulating lncRNAs H19 and GAS5 in type 2 diabetes mellitus (T2DM) and diabetic retinopathy (DR) is not clear. Here, we assessed the plasma levels of H19 and GAS5 lncRNAs in T2DM patients with/without DR and evaluated if H19 and GAS5 pre-treatment plasma levels are a predictor of early response to a single aflibercept dose in DR subgroup. Plasma lncRNA expression profiles of 119 T2DM patients (66 with DR and 53 without DR) and 110 healthy controls were determined by quantitative reverse transcription PCR. The association of lncRNA expression profiles with clinical features and aflibercept early response in DR patients was investigated. Relative H19 expression levels were significantly increased in T2DM group (including DR and non-DR subgroups) vs. controls, while GAS5 levels were decreased in T2DM group (p < 0.001). There was no significant difference in H19 and GAS5 expression levels between DR and non-DR subgroups. H19 and GAS5 expression profiles were not significantly correlated with clinical parameters or response to aflibercept therapy in DR subgroup. Our findings indicate that the circulating lncRNAs H19 and GAS5 may be associated with T2DM prevalence but may not have an important diagnostic/prognostic role in DR or early response to aflibercept intravitreal injection in DR patients. Large-scale transcriptomic studies are warranted to validate our results and investigate other lncRNA candidates in T2DM.

1 August 2021 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
HMHala Mohammad
Hala Mohammad
AAAhmed A Abdelghany
Ahmed A Abdelghany
EAEssam Al Ageeli
Essam Al Ageeli
SKShahad W. Kattan
Shahad W. Kattan
RHRanya Moustafa Hassan
Ranya Moustafa Hassan
NMNaglaa Mokhtar
Naglaa Mokhtar
Background: Long non-coding RNAs (lncRNAs) play essential roles in molecular diagnosis and therapeutic response in several diseases. Purpose: For the first time, we aimed to evaluate the association of four lncRNAs TUG1 (rs7284767G/A), MIAT (rs1061540T/C), MALAT1 (rs3200401C/T), and SENCR (rs12420823C/T) variants with susceptibility to diabetic retinopathy (DR), disease severity, and early therapeutic response to intravitreous anti-vascular endothelial growth factor aflibercept therapy. Patients and Methods: This case-control study enrolled 126 adult patients with type 2 diabetes. TaqMan assays using Real-Time PCR were run for genotyping. Multivariable regression analyses were applied to assess the role of each polymorphism after the adjustment of covariates. Results: Carriers of TUG1 A/G and MIAT T/C and C/C genotypes were more likely to develop DR [OR=3.15 (95% CI=1.15– 8.64), and OR=4.31 (95% CI=1.78– 10.47)], while MALAT1 T/C conferred protection (OR=0.40, 95% CI=0.16– 0.99). For TUG1, MALAT1, MIAT, and SENCR genotype combinations, GTCT and GCCC had a higher disease risk (P=0.012). For disease severity, MIAT T/T homozygosity was associated with higher DR grade [33.3% (T/T) vs 10% (C/C) and 4.2% (C/T) carriers, P=0.012]. Otherwise, patients with the SENCR T variant exhibited better pre-treatment best-corrected visual acuity level (p=0.021). Following aflibercept administration, carrying the TUG1 A or MIAT T/C was associated with a poor therapeutic response (OR=5.02, 95% CI=1.60– 15.76, and OR=10.23, 95% CI=1.51– 69.15, respectively). Conclusion: The lncRNAs TUG1 (rs7284767G/A) and MIAT (rs1061540T/C) were associated with increased DR susceptibility and poor response to aflibercept treatment, while MALAT1 (rs3200401C/T) conferred protection to DR. These genetic determinants could be useful in DR risk stratification and pharmacogenetics after validation in large-scale studies.

23 April 2019 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
EMEhab M. Moawad
Ehab M. Moawad
AEAhmed A. Abd Elghany
Ahmed A. Abd Elghany
AGAmr A. Gab-Alla
Amr A. Gab-Alla
OEOsama M. Elbassiouny
Osama M. Elbassiouny
MBMohsen S. Badawy
Mohsen S. Badawy
The study aimed to assess the role of intraoperative mitomycin-C (MMC) application during hyperopic LASIK correction (+ 1.00 D to + 6.00 D) by examining topographic corneal changes and incidence of regression over a one-year follow-up period. This comparative randomized control study included 68 hyperopic patients (136 eyes) divided into two groups; Group A included 34 patients (68 eyes) that had LASIK with the application of 0.02% MMC for 10 s on the stromal bed after excimer laser treatment, and group B included 34 patients (68 eyes) that had LASIK without MMC application. Uncorrected distance visual acuity (UDVA), refraction, keratometry and topography were recorded at 1st week and 1st, 3rd, 6th, and 12th months postoperation. Predictability and treatment efficacy were also recorded at the end of the follow-up period. Better predictability was noted in group A than in group B at the 6 month and 12 month follow-up visits, with a mean cycloplegic refraction SE of + 0.5 ± 0.31 D in group A and + 0.67 ± 0.39 D in group B at the 6 month visit, and + 0.63 ± 0.37 D in group A and + 0.89 ± 0.48 D in group B at the 12 month visit. The efficacy of the treatment at the end of the follow up period was better in group A than in group B. Group A showed fewer topographic corneal changes than group B. Intraoperative MMC application during hyperopic LASIK achieves better predictability and efficacy and induces fewer topographic changes and lower regression rate of hyperopia during the first postoperative year. the Pan African Clinical Trial Registry PACTR201901543722087 , on 29 January 2019.

8 September 2019 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
AAAhmed A. Abdelghany
Ahmed A. Abdelghany
MSMoataz A. Sallam
Moataz A. Sallam
AEAbdallah A Ellabban
Abdallah A Ellabban
Purpose. To assess eye pressure, ganglion cell complex, and retinal nerve fiber layer changes following cataract surgery in patients with pseudoexfoliation glaucoma.Methods. Eighty-five patients with pseudoexfoliation glaucoma (PEXG) were included in the study. They were divided into two groups; the first group included patients with PEXG and cataract who underwent phacoemulsification (pseudophakic group;n = 40 eyes). The second group included patients with PEXG without cataract (control group;n = 45 eyes). Both groups were on antiglaucoma treatment. IOP changes after surgery and the ganglion cell complex (GCC) and peripapillary retinal nerve fiber layer (pRNFL) thicknesses were evaluated in patients underwent cataract extraction surgery compared to controls that did not have cataract, nor underwent surgery. Both groups were followed up postoperatively for 18 months.Results. There was no difference in the mean age and glaucoma stage in both groups (P=0.242and 0.70, respectively). In the pseudophakic group, the mean IOP significantly dropped from 20.43 ± 0.90 to 17.00 ± 2.75 mmHg at the end of the follow-up period (P≤0.001). Slight decrease (≈3 μm) was recorded in the mean GCC thickness of the pseudophakic patients from the baseline at the end of the follow-up period. This decrease was lower than that of the controls (≈5 μm). No significant pRNFL changes were recorded all over the postoperative visits (88.78 ± 22.55 μm at 3 months, 88.67 ± 23.14 μm at 6 months, 87.62 ± 23.04 μm at 12 months, and 87.32 ± 22.61 μm at 18 months) as compared to preoperative value (90.28 ± 22.31 μm) withP=0.335, 0.387, 0.158, and 0.110, respectively, or controls (89.69 ± 21.76 μm, 88.73 ± 21.08 μm, 87.33 ± 20.67 μm, and 87.23 ± 20.54 μm withP=0.850, 0.990, 0.951, and 0.984).Conclusion. Phacoemulsification and IOL implantation may aid in managing pseudoexfoliation glaucoma by lowering IOP and slowing the rate of GCC and pRNFL losses over a short-term period.